Analyst Activity – Needham & Company LLC Reiterates Buy on GenMark Diagnostics (NASDAQ:GNMK)

ME Staff
-
0

Analyst Ratings For GenMark Diagnostics (NASDAQ:GNMK)

Today, Needham & Company LLC reiterated its Buy rating on GenMark Diagnostics (NASDAQ:GNMK) with a price target of $11.00.

Some recent analyst ratings include

  • 1/19/2018-Needham & Company LLC Reiterated Rating of Buy.
  • 11/3/2017-Cowen Reiterated Rating of Buy.
  • 11/3/2017-Raymond James Financial Reiterated Rating of Outperform .
  • 10/30/2017-Canaccord Genuity Reiterated Rating of Buy.
  • 9/18/2017-Bank of America initiated coverage with a Buy rating.


  • On 12/4/2017 Michael Gleeson, SVP, sold 499 with an average share price of $4.70 per share and the total transaction amounting to $2,345.30.
  • On 11/20/2017 Hany Massarany, Insider, sold 8,252 with an average share price of $4.74 per share and the total transaction amounting to $39,114.48.
  • On 11/20/2017 Jennifer Anne Williams, SVP, sold 2,719 with an average share price of $4.74 per share and the total transaction amounting to $12,888.06.
  • On 11/20/2017 Scott Mendel, CFO, sold 2,879 with an average share price of $4.74 per share and the total transaction amounting to $13,646.46.
  • On 11/14/2017 Scott Mendel, CFO, sold 1,777 with an average share price of $4.71 per share and the total transaction amounting to $8,369.67.
  • On 11/6/2017 Michael Kagnoff, Director, bought 20,000 with an average share price of $4.13 per share and the total transaction amounting to $82,600.00.
  • On 11/2/2017 Eric Stier, SVP, sold 367 with an average share price of $7.24 per share and the total transaction amounting to $2,657.08.

Recent Trading Activity for GenMark Diagnostics (NASDAQ:GNMK)
Shares of GenMark Diagnostics closed the previous trading session at 4.70 down -0.01 0.21% with 4.760000228881836 shares trading hands.